Steven D. Cosler
Steven D. Cosler's purchase track record
How the stock did after each of Steven D. Cosler's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/3/2025 | GRDN | $100K | +18.8% | +33.8% | +10.3% |
| 11/19/2024 | GRDN | $149K | -7.0% | +22.9% | +0.4% |
| 9/27/2024 | GRDN | $100K | +19.5% | +13.5% | -2.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Truist covers NNN REIT, cites occupancy strategy. Truist Securities began coverage of NNN REIT with a Hold rating and set a price target of $45. Recent analyst commentary highlights the company's occupancy‑driven investment approach as a key strength. Dividend‑focused articles continue to list NNN among REITs expected to hold up despite higher interest rates. The stock is currently near its long‑standing support level of $43.09.
Transaction History
| GRDN | ▲ Buy | Grant | 4,028 | $0 | 5/5/2026 | View on chart |
| NNN | ▲ Buy | Grant | 1,568 | $66K | 1/30/2026 | View on chart |
| GRDN | ▲ Buy | Open Market | 3,370 | $100K | 12/3/2025 | View on chart |
| NNN | ▲ Buy | Grant | 1,583 | $65K | 10/31/2025 | View on chart |
| NNN | ▲ Buy | Grant | 1,492 | $63K | 7/31/2025 | View on chart |
| GRDN | ▲ Buy | Grant | 3,901 | $0 | 5/9/2025 | View on chart |
| NNN | ▲ Buy | Grant | 1,497 | $62K | 4/30/2025 | View on chart |
| NNN | ▲ Buy | Grant | 1,538 | $61K | 1/31/2025 | View on chart |
| GRDN | ▲ Buy | Open Market | 7,000 | $149K | 11/19/2024 | View on chart |
| NNN | ▲ Buy | Grant | 2,386 | $110K | 10/31/2024 | View on chart |
| GRDN | ▲ Buy | Open Market | 7,142 | $100K | 9/27/2024 | View on chart |
| GRDN | ▲ Buy | Grant | 3,571 | $0 | 9/27/2024 | View on chart |
| NNN | ▲ Buy | Grant | 2,337 | $108K | 7/31/2024 | View on chart |
| NNN | ▲ Buy | Grant | 2,615 | $106K | 4/30/2024 | View on chart |
| NNN | ▲ Buy | Grant | 2,583 | $105K | 1/31/2024 | View on chart |
| NNN | ▲ Buy | Grant | 516 | $18K | 10/31/2023 | View on chart |
| NNN | ▲ Buy | Grant | 1,730 | $61K | 10/31/2023 | View on chart |
| NNN | ▲ Buy | Grant | 1,430 | $61K | 7/31/2023 | View on chart |
| NNN | ▲ Buy | Grant | 410 | $18K | 7/31/2023 | View on chart |
| NNN | ▲ Buy | Grant | 1,298 | $56K | 4/28/2023 | View on chart |
| NNN | ▲ Buy | Grant | 405 | $17K | 4/28/2023 | View on chart |
| NNN | ▲ Buy | Grant | 1,186 | $56K | 1/31/2023 | View on chart |
| NNN | ▲ Buy | Grant | 365 | $17K | 1/31/2023 | View on chart |
| NNN | ▲ Buy | Grant | 1,328 | $56K | 10/31/2022 | View on chart |
| NNN | ▲ Buy | Grant | 404 | $17K | 10/31/2022 | View on chart |
| NNN | ▲ Buy | Grant | 1,182 | $56K | 7/29/2022 | View on chart |
| NNN | ▲ Buy | Grant | 343 | $16K | 7/29/2022 | View on chart |
| NNN | ▲ Buy | Grant | 1,214 | $56K | 4/29/2022 | View on chart |
| NNN | ▲ Buy | Grant | 347 | $16K | 4/29/2022 | View on chart |
| NNN | ▲ Buy | Grant | 2,300 | $99K | 2/11/2022 | View on chart |
| NNN | ▲ Buy | Grant | 1,282 | $56K | 1/31/2022 | View on chart |
| NNN | ▲ Buy | Grant | 363 | $16K | 1/31/2022 | View on chart |
| NNN | ▲ Buy | Grant | 2,011 | $93K | 10/29/2021 | View on chart |
| NNN | ▼ Sell | Other | 3,676 | $92K | 10/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Guardian Pharmacy Services Q2 2026 Earnings Call Highlights
Guardian Pharmacy Services held its Q2 2026 earnings conference call, reviewing the quarter’s financial results and outlook. Management addressed performance metrics and future expectations, offering insight for investors. The discussion comes as the stock trades near its recent support level of $40.33, with an RSI around 40, indicating modest momentum.
Guardian Pharmacy Services Q2 2026 Earnings Call Highlights. Guardian Pharmacy Services held its Q2 2026 earnings conference call, reviewing the quarter’s financial results and outlook. Management addressed performance metrics and future expectations, offering insight for investors. The discussion comes as the stock trades near its recent support level of $40.33, with an RSI around 40, indicating modest momentum.